share_log

Today's biggest pre-market stock movers: Puxin, Jasper Therapeutics, Waitr Holdings and more

Today's biggest pre-market stock movers: Puxin, Jasper Therapeutics, Waitr Holdings and more

今天最大的盘前股票推动者：朴新教育、贾斯珀治疗公司、维特控股等
Benzinga Real-time News ·  2021/10/13 07:58  · 异动

Gainers

赢家


Losers

失败者

  • $Neuronetics Inc(STIM.US)$ shares fell 26.9% to $4.68 in pre-market trading after the company lowered its sales guidance. BTIG downgraded Neuronetics from Buy to Neutral.

  • $Regulus Therapeutics Inc(RGLS.US)$ shares fell 25% to $0.57 in pre-market trading after the company announced a strategic prioritization of its next-generation candidate, RGLS8429, for the treatment of ADPKD. The company's previous ADPKD candidate, RGLS4326, will no longer be advanced.

  • $CytoSorbents Corp(CTSO.US)$ shares fell 9.8% to $6.25 in pre-market trading after the company reported preliminary Q3 results and received full FDA Investigational Device Exemption approval to begin US STAR-D trial on apixaban and rivaroxaban removal by DrugSorb-ATR antithrombotic removal system during urgent cardiothoracic surgery.

  • $NUTRIBAND INC(NTRB.US)$ fell 8.7% to $8.86 in pre-market trading. Nutriband shares jumped 31% on Tuesday after the company announced it signed an exclusive manufacturing agreement for Diocheck visual COVID-19 antibody indicator patch.

  • $NRX Pharmaceuticals(NRXP.US)$ fell 7.8% to $10.06 in pre-market trading. NRX Pharmaceuticals shares jumped 61% on Tuesday after the company announced progress on the worldwide commercial scale development of ZYESAMI.

  • $Apollo Endosurgery Inc(APEN.US)$ fell 7.6% to $7.84 in pre-market trading after the company reported pricing of $65 million public offering of common stock.

  • $ZIVO BIOSCIENCE(ZIVO.US)$ fell 6.5% to $4.19 in pre-market trading after gaining over 18% on Tuesday.

  • $CRISPR Therapeutics AG(CRSP.US)$ shares fell 5.8% to $96.70 in pre-market trading after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies.

  • $Neuronetics Inc.(STIM.US)$在该公司下调销售指引后，股价在盘前交易中下跌26.9%，至4.68美元。BTIG将Neuronetics评级从买入下调至中性。

  • $Regulus治疗公司(RGLS.US)$在盘前交易中，该公司股价下跌25%，至0.57美元，此前该公司宣布对其治疗ADPKD的下一代候选药物RGLS8429进行战略优先排序。该公司之前的ADPKD候选人RGLS4326将不再高级。

  • $CytoSorbents Corp(CTSO.US)$在盘前交易中，该公司股价下跌9.8%，至6.25美元，此前该公司报告了第三季度的初步业绩，并获得FDA全面的调查设备豁免批准，开始在美国STAR-D试验中使用DrugSorb-ATR抗血栓清除系统在紧急心胸手术期间去除apixaban和rivaroxaban。

  • $NUTRIBAND Inc.(NTRB.US)$在盘前交易中，该股下跌8.7%，至8.86美元。周二，在公司宣布签署了Diocheck视觉新冠肺炎抗体指示器贴片的独家制造协议后，Nutriband的股价上涨了31%。

  • $NRX制药公司(NRXP.US)$在盘前交易中下跌7.8%，至10.06美元。NRX PharmPharmticals股价周二大涨61%，此前该公司宣布ZYESAMI的全球商业规模开发取得进展。

  • $阿波罗内科手术公司(APEN.US)$在盘前交易中，该公司股价下跌7.6%，至7.84美元，此前该公司公布普通股公开发行定价为6500万美元。

  • $Zivo Bioscience(ZIVO.US)$在周二上涨超过18%后，该公司在盘前交易中下跌6.5%，至4.19美元。

  • $CRISPR Treateutics AG(CRSP.US)$在盘前交易中，该公司股价下跌5.8%，至96.70美元，此前该公司公布了CTX110治疗复发或难治性CD19+B细胞恶性肿瘤的第一阶段碳试验结果。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发